395 related articles for article (PubMed ID: 30875800)
1. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model.
Cho EJ; Yu SJ; Kim K; Cho H; Cho YY; Lee YB; Lee JH; Kim YJ; Youn H; Yoon JH
J Bioenerg Biomembr; 2019 Apr; 51(2):121-129. PubMed ID: 30746618
[TBL] [Abstract][Full Text] [Related]
3. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2.
Xu D; Jin J; Yu H; Zhao Z; Ma D; Zhang C; Jiang H
J Exp Clin Cancer Res; 2017 Mar; 36(1):44. PubMed ID: 28320429
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
5. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
[TBL] [Abstract][Full Text] [Related]
6. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition.
Yu SJ; Yoon JH; Yang JI; Cho EJ; Kwak MS; Jang ES; Lee JH; Kim YJ; Lee HS; Kim CY
J Bioenerg Biomembr; 2012 Feb; 44(1):101-15. PubMed ID: 22350012
[TBL] [Abstract][Full Text] [Related]
8. Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Harati R; Vandamme M; Blanchet B; Bardin C; Praz F; Hamoudi RA; Desbois-Mouthon C
Mol Pharmacol; 2021 Jul; 100(1):32-45. PubMed ID: 33990407
[TBL] [Abstract][Full Text] [Related]
9. Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells.
Chen X; Zhu N; Wu Y; Zhang Y; Zhang Y; Jin K; Zhou Z; Chen G; Wang J
Phytomedicine; 2024 Jun; 128():155317. PubMed ID: 38537439
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
12. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
[No Abstract] [Full Text] [Related]
13. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
14. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Jeong JM; Cheon GJ; Lee TS; Yang JI; Park SC; Lee HS
Mol Cancer Ther; 2007 Sep; 6(9):2554-62. PubMed ID: 17876052
[TBL] [Abstract][Full Text] [Related]
16. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
[TBL] [Abstract][Full Text] [Related]
17. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
18. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
19. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
20. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
